Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 14,388 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Clear all
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

NCT04715048
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
PrabotulinumtoxinA, Onabotulinum toxin A
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 21, 2026, 5:04 PM EDT
Not listed Phase 1Phase 2 Interventional

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

NCT05288725
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate
Biological · Drug · Device
Lead sponsor
Next Generation Regenerative Medicine LLC
Network
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Indocyanine Green for Central Nervous System Tumors

NCT02710240
View directory record Official record
Conditions
Suspected Central Nervous System Tumors
Interventions
Indocyanine Green (ICG), Intraoperative near-infrared (NIR)
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 4 Interventional Results available

Lipid Management in Renal Transplant Recipients Using Evolocumab.

NCT04608474
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Evolocumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Phase 4 Interventional

Assessing Optimal XRB Initiation Points in Jail

NCT06051890
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Extended-Release Buprenorphine (XRB), Sublingual Buprenorphine (SLB)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Springfield, Massachusetts • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Phase 1 Interventional

TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

NCT07189195
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
Interventions
TR-002
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

NCT00726544
View directory record Official record
Conditions
Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
Interventions
ARC 1779 Placebo, ARC1779 Injection
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes

NCT01475734
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional Results available

Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

NCT00064987
View directory record Official record
Conditions
Hypogonadism, Kallmann Syndrome
Interventions
Testicular biopsy, gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH)
Procedure · Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

NCT04576793
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, 18F-MK6240, 18F-Florbetaben, Lumbar Puncture
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

NCT00345293
View directory record Official record
Conditions
Prostate Cancer
Interventions
autologous dendritic cell vaccine (DC/PC3)
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair

NCT02056301
View directory record Official record
Conditions
Pectus Excavatum
Interventions
Hydromorphone, Morphine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 18 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Not applicable Interventional Results available

Study to Evaluate Safety & Effectiveness of Vascular Sealant System

NCT00439309
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Gelfoam/Thrombin, VascuSeal
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)

NCT00968409
View directory record Official record
Conditions
Breast Cancer
Interventions
PET, Laboratory Testing, Safety Testing, F18-FFNP
Radiation · Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients

NCT00630799
View directory record Official record
Conditions
Prostate Cancer
Interventions
leuprolide acetate
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
New Port Richey, Florida • Lawrenceville, New Jersey • Poughkeepsie, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

NCT02503332
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Pegcetacoplan, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

NCT03610581
View directory record Official record
Conditions
Human Papillomavirus Infections
Interventions
Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

NCT02873819
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
GL-0817, Hiltonol, Sargramostim, cyclophosphamide, Placebo
Drug
Lead sponsor
Gliknik Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 21, 2026, 5:04 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

NCT05128344
View directory record Official record
Conditions
Spasms, Infantile
Interventions
AMZ002 injectable solution, 0.5mg/mL, Vigabatrin, oral
Drug
Lead sponsor
Amzell
Industry
Eligibility
2 Months to 24 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Aurora, Colorado • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Collagen Injections for the Treatment of Acne Scars and Wrinkles

NCT01704209
View directory record Official record
Conditions
Acne Scars, Wrinkles
Interventions
Fibroblast Treatment, Vehicle
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

NCT06427798
View directory record Official record
Conditions
Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
Interventions
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Phase 1 Interventional

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

NCT05686798
View directory record Official record
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme, GBM
Interventions
Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

NCT02206087
View directory record Official record
Conditions
Healthy
Interventions
PER977, Placebo, Heparin Sodium
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional Results available

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

NCT00711087
View directory record Official record
Conditions
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions
BOTOX-A, Saline injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 21, 2026, 5:04 PM EDT